Novocure NVCR Q3 2016 Earnings Results

Novocure's Q3 2016 financial and operational results presentation, highlighting strong growth in Optune prescriptions and active patients following FDA approval for glioblastoma treatment. Results demonstrate 94% year-over-year prescription growth, with expansion across U.S. and European markets.